Evidence map›Paper›PMID 30156755›Full record

ArticleStem cells translational medicine2019

Autologous Endothelial Progenitor Cells Transplantation for Acute Ischemic Stroke: A 4-Year Follow-Up Study.

Jie Fang, Yang Guo, Sheng Tan, Zhanhui Li, Huifang Xie, Pingyan Chen, Kai Wang, Zhicong He, Peng He, Yiquan Ke and 2 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01468064 (Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Patients With Ischemic Stroke), which is not on this map. Cited by 61 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 7 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01468064 phase1 / phase2completednot on this map

Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Patients With Ischemic Stroke: a Randomized Controlled Trial

TypeinterventionalSponsorSouthern Medical University, ChinaRan2011 to 2017Enrolled20ConditionsStroke, Infarction, Middle Cerebral ArteryArmsAutologous BMSCs transplantation, Autologous EPCs transplantation, IV infusion of placebo
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 7 syntheses or guidelines pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. A review and meta-analysis of stem cell therapies in stroke patients: effectiveness and safety evaluation.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Randomized placebo-controlled trial of CL2020, an allogenic muse cell-based product, in subacute ischemic stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Trial
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jie FangDepartment of Neurosurgery, Zhujiang Hospital, Southern Medical University, The National Key Clinical Specialty, Guangzhou, People's Republic of China.ORCID 0000-0002-9309-061X
Yang GuoDepartment of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Sheng TanDepartment of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Zhanhui LiDepartment of Neurology, General Hospital's Nanhai Hospital, The Second People's Hospital of Nanhai District, Foshan City, Foshan, Guangdong, People's Republic of China.
Huifang XieDepartment of Neurology, Zhujiang Hospital, Southern Medical University, Guangzhou, People's Republic of China.
Pingyan ChenDepartment of Biostatistics, Southern Medical University, Guangzhou, People's Republic of China.
Kai WangDepartment of Biostatistics, Southern Medical University, Guangzhou, People's Republic of China.
Zhicong HeDepartment of Neurology, General Hospital's Nanhai Hospital, The Second People's Hospital of Nanhai District, Foshan City, Foshan, Guangdong, People's Republic of China.
Peng HeDepartment of Neurology, General Hospital's Nanhai Hospital, The Second People's Hospital of Nanhai District, Foshan City, Foshan, Guangdong, People's Republic of China.
Yiquan KeDepartment of Neurosurgery, Zhujiang Hospital, Southern Medical University, The National Key Clinical Specialty, Guangzhou, People's Republic of China.
Xiaodan JiangDepartment of Neurosurgery, Zhujiang Hospital, Southern Medical University, The National Key Clinical Specialty, Guangzhou, People's Republic of China.
Zhenzhou ChenDepartment of Neurosurgery, Zhujiang Hospital, Southern Medical University, The National Key Clinical Specialty, Guangzhou, People's Republic of China.ORCID 0000-0003-3600-4292
Southern Medical University · CNZhujiang Hospital · CNFoshan Second People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transplantation of endothelial progenitor cells (EPCs) is a proven safe and effective method for treatment of cerebral ischemia in animal experiments. However, safety and efficacy need to be determined in clinical trials. We performed a two-center, randomized, placebo-controlled phase I/IIa trial with blinded outcome assessment on 18 patients with acute cerebral infarct within the middle cerebral artery territory, and followed for up to 4 years. Autologous ex vivo expanded EPCs were injected intravenously in the EPC group, and patients who received saline or autologous bone marrow stromal cells served as control groups. Mortality of any cause, adverse events, and new-onset comorbidities were monitored. Changes in neurological deficits were assessed at different time points. We found no toxicity events or infusional or allergic reactions in any treated group. Three patients in the placebo group died during the 4-year follow-up. We found that the EPC group had fewer serious adverse events compared with the placebo-controlled group, although there were no statistical differences in mortality among the three groups. Furthermore, there was no significant difference in neurological or functional improvement observed among the three groups, except for the Scandinavia Stroke Scale score at 3 months between the EPC group and placebo-controlled group. Autologous transplantation of EPCs appears to improve long-term safety in acute cerebral infarct patients, supporting the feasibility of this novel method for treatment of ischemic stroke (ClinicalTrials.gov: NCT01468064). Stem Cells Translational Medicine 2019;8:14-21.

Indexed as

AdultAgedCell SurvivalEndothelial Progenitor CellsFemaleHumansMaleMesenchymal Stem CellsMiddle AgedStrokeTransplantation, AutologousBone marrow stromal cellsClinical trialEndothelial progenitor cellsStrokeTransplantation

Identifiers

PMID30156755
PMCPMC6312444
OpenAlexW2888798518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.